1548P - Is there a relationship between patient's satisfaction of the diagnosis announcement device and chemotherapy-induced nausea and vomiting?

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Complications of Treatment
Supportive Care
Presenter Sophie Gouerant
Citation Annals of Oncology (2014) 25 (suppl_4): iv517-iv541. 10.1093/annonc/mdu356
Authors S. Gouerant1, A.E. Dugue2, J. Vanboeckstael3, D. Allouache1, S. Noal1, A. Faveyrial1, C. Delcambre1, M. Galais1, A. Lefebvre1, E. Sevin1, F. Polycarpe1, I. Hrab1, P.E. Brachet1, L. Kaluzinski4, M.D. Ngo5, B. Vie6, N. Lemenand2, J. Grellard2, B. Clarisse2, F. Joly Lobbedez1
  • 1Oncology, Centre Francois Baclesse, 14000 - CAEN/FR
  • 2Clinical Research, Centre Francois Baclesse, 14000 - CAEN/FR
  • 3Oncology, Centre Hospitalier de Compiègne, Compiègne/FR
  • 4Oncology, Centre Hospitalier, Cherbourg/FR
  • 5Oncology, Centre Hospitalier Jacques Monod, Flers/FR
  • 6Oncology, Polyclinique du Parc, Caen/FR



The announcement device was an emblematic measure of the first French Plan Cancer aiming at enabling patients to have a listening and information time after diagnosis announcement and treatment proposition: the different aspects of the treatments including side effects are discussed during these specific clinics. This procedure includes a medical and paramedical consultation. Nausea and vomiting (CINV) are still one of the most common side effects of the chemotherapy (CT) despite of known risk factors and efficient supportive treatments. Hypothesizing patients with good information on CINV and preventive supportive treatments may have less CINV, our study aimed to assess the relation between the patient's satisfaction of information delivered during the diagnosis announcement procedure and the incidence of CINV after the first cycle of chemotherapy.


This prospective multicentric study assessed the frequency and intensity of CINV among patients naïve of CT after the first cycle of treatment, using the MASCC Antiemesis Tool (MAT). CINV were defined by≥1 emetic episode or reported nausea intensity≥3 on a 0-10 scale. Multivariate analysis was used to identify various factors related to overall CINV onset, including satisfaction defined as a satisfaction score equal or above median on a 0-10 scale for≥1 announcement consultation.


Data from 291 patients (women: 85.2%; mean age: 57 years) from 4 centers were analyzed. Median satisfaction score were 9 and 10 for medical/paramedical consultations (1st quartile: 8 and 9, respectively): 67% of patients were satisfied of announcement device. 40.4% of patients reported acute CINV, 34.8% delayed CINV and 52.4% overall CINV. Four independent predictive factors of CINV were found: motion sickness history (OR 2.73), highly emetogenic CT (OR 2.12), anxiety (OR 2.09) and age under 57 (OR 1.99). No relation was noted between announcement consultation satisfaction and risk of CINV.


The announcement consultation satisfaction was not linked to lower CINV frequency. In fact, even "unsatisfied" patients gave a high score, not allowing to clearly identify the impact of satisfaction on CINV.


All authors have declared no conflicts of interest.